Evopoint Biosciences Inc.
Clinical trials sponsored by Evopoint Biosciences Inc., explained in plain language.
-
New hope for Tough-to-Treat lymphoma: experimental pill shows promise
Disease control Recruiting nowThis study tests an experimental drug called XNW5004 in 65 adults with follicular lymphoma (a slow-growing blood cancer) that has returned or stopped responding after at least three prior treatments. Participants take the drug twice daily for 28-day cycles. Researchers will measu…
Phase: PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug XNW28012 tested in advanced cancers – hope for tumor control
Disease control Recruiting nowThis study tests a new drug called XNW28012 in adults with advanced solid tumors (like pancreatic, ovarian, cervical, or colorectal cancer) that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 350 people…
Phase: PHASE1, PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for rare blood cancer: phase 3 trial of XNW5004 launches
Disease control Recruiting nowThis study tests a new drug, XNW5004, against an existing treatment (Chidamide) for people with a rare blood cancer called peripheral T-cell lymphoma that has come back or not responded to prior therapy. About 120 adults aged 18-70 will participate. The main goal is to see if XNW…
Phase: PHASE3 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated May 08, 2026 12:01 UTC